Benefits of Elevess



  • Natural and immediate effect
  • Long-lasting results
  • Ease of injection
  • Minimized injection pain

ELEVESS™, like other dermal fillers, is injected directly into patients’ skin; however ELEVESS is the first FDA-approved HA-based dermal filler to include the anesthetic lidocaine, greatly reducing injection pain and increasing patient comfort.

Long-lasting*, more natural effects are the result of a unique, patented hyaluronic acid cross-linker and the highest concentration of HA of any available dermal filler.

Additional benefits of ELEVESS include an ergonomically designed syringe for ease of handling and unique properties that allow for easy injection through a very thin (30G) needle to minimize patient discomfort.

Risks/Contraindications:

ELEVESS is composed of cross-linked hyaluronic acid and lidocaine, and contains sodium metabisulfite as an antioxidant. It may contain trace amounts of gram positive bacterial proteins. In rare occasions in certain susceptible people, sulfites (such as a metabisulfite) may cause allergic-type reactions (refer to professional product labeling for a complete list of warnings and precautions). ELEVESS is contraindicated in patients with a history of allergies to such material. ELEVESS is also contraindicated in patients with severe allergies manifested by a history of anaphylaxis or a history or presence of multiple severe allergies.

Important safety considerations:

ELEVESS is indicated to correct moderate to severe facial wrinkles and folds (such as nasolabial folds). It is injected directly into the skin. Extensive pre-approval clinical studies demonstrated the safety and efficacy of ELEVESS. Some bruising, swelling, redness, tenderness, itching and nodule (small bumps) formation were recorded in clinical trials and may occur after injection. This will normally last less than seven days. Until the initial bruising and swelling is resolved, exposure to sun or other UV sources and extreme cold should be minimized.

In rare circumstances, other complications could occur (refer to product labeling for complete warnings and precautions information). More prominent bruising and bleeding may occur with people who are taking anti-coagulant drugs (blood thinners). The safety of ELEVESS for pregnant and nursing women has not been investigated. ELEVESS should be used with caution in people undergoing immunosuppressive therapy. Subsequent laser treatment, chemical peeling or other dermal procedures may cause a possible risk of inflammatory response at the injection site. This also applies if ELEVESS is administered before the skin has healed after such procedures. The use of ELEVESS should be postponed in the case of certain inflammatory skin disorders, such as skin sores, rashes, cysts, hives or infection at the injection site.

* A recently completed clinical study of ELEVESS in the EU suggests that the product continues to demonstrate efficacy in a significant percentage of patients up to 1 year after treatment.